Loading...
Avanos Q1 2025 Earnings Report
Avanos Medical, Inc. announced its first quarter 2025 results, reporting an increase in net sales and operating income compared to the prior year period.
Key Takeaways
Avanos Medical, Inc. reported net sales of $167.5 million for the first quarter of 2025, an increase of 0.8% year-over-year. The company's net income was $6.6 million, and adjusted diluted earnings per share were $0.26. Operating income significantly improved to $10.3 million from $4.0 million in the prior year.
Net sales for Q1 2025 increased by 0.8% to $167.5 million.
Operating income rose to $10.3 million in Q1 2025, up from $4.0 million in Q1 2024.
Adjusted diluted earnings per share were $0.26, compared to $0.22 in the prior year.
Cash flow from operations was an inflow of $25.7 million, a significant improvement from an outflow of $8.0 million a year ago.
Revenue by Segment
Forward Guidance
Avanos Medical is maintaining its 2025 estimated revenue guidance but lowering its estimated adjusted diluted earnings per share range due to the impact of recently announced tariffs.
Positive Outlook
- Maintaining 2025 estimated revenue guidance between $665 million and $685 million.
- Management plans to mitigate tariff impact through cost containment measures.
- Leveraging USMCA and other existing international agreements for reduced or duty-free importation.
- Commitment to delivering clinically superior solutions for patients.
- Focus on addressing important healthcare needs like nutrition and pain management.
Challenges Ahead
- Lowering estimated adjusted diluted earnings per share to between $0.75 and $0.95.
- The primary reason for the lowered EPS guidance is the impact of recently announced tariffs.
- Assumes tariffs on China-origin goods will be in effect.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...